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Edited by Ned ManteiAbstract Serotonin (5-HT) derived from bulbo-spinal projec-
tion is released by nociceptive input into the spinal dorsal horn.
Here we report that formalin injection in the paw produced pain
behavior (ﬂinching) and phosphorylation of spinal ERK1/2 (P-
ERK1/2, indicating activation) in rats. Depletion of spinal 5-
HT by intrathecal (IT) 5,7-DHT, a serotonergic neurotoxin,
profoundly reduced formalin evoked ﬂinching and the increase
in P-ERK1/2. Ondansetron (a 5-HT3 receptor antagonist) at
IT doses that inhibited ﬂinching also attenuated spinal ERK acti-
vation. These ﬁndings reveal that primary aﬀerent-evoked acti-
vation of spinal ERK requires the input from an excitatory 5-
HT descending pathway.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Several reports indicate that extracellular signal-regulated
kinases 1 and 2 (ERK1/2) expressed in the spinal cord are in-
volved in pain signal processing. ERK1/2 are activated in the
spinal dorsal horn following peripheral inﬂammation and tis-
sue/nerve injury. Pharmacologically blocking this activation
reduces the hypersensitivity otherwise observed in these exper-
imental models [1–5]. Current thinking has been that this acti-
vation of ERK is directly mediated by a local aﬀerent evoked
excitation of the dorsal horn neurons. This assertion, while
reasonable, ignores the possible contribution of other dorsal
horn inputs that are believed to regulate dorsal horn excitabil-
ity. The excitatory serotonergic pathway, which arises from the
brainstem medullary 5-hydroxytrytamine (5-HT) containing
nuclei of the caudal midline raphe [6–8], plays a signiﬁcant role
in controlling spinal excitability through activation of spinal 5-
HT3 receptors [6,9–11]. These observations led us to advance
the hypothesis that spinal ERK1/2 activation observed in theAbbreviations: ERK, extracellular signal-regulated protein kinase; IT,
intrathecal; NK1, neurokinin 1; P-ERK, phosphorylated extracellular
signal-regulated protein kinase; 5-HT, 5-hydroxytrytamine
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doi:10.1016/j.febslet.2006.11.012face of noxious aﬀerent stimulation is in fact mediated by this
descending pathway.2. Materials and methods
2.1. Animals
All experiments were carried out according to protocols approved by
the Institutional Animal Care Committee of University of California,
San Diego. Male Holzman Sprague–Dawley rats (300–350 g) were
used. Chronic lumbar intrathecal (IT) catheters (PE-5, 8.5 cm) were
implanted through a cisternal exposure under isoﬂurane anesthesia
[12]. PD98059 (Calbiochem, San Diego, CA), 5,7-dihydroxy-trypt-
amine (5,7-DHT, Sigma), and Ondansetron hydrochloride (ZofranR,
GlaxoSmithKline, UK) were prepared for IT delivery in 10 ll followed
by 10 ll saline. PD98059 was dissolved in 25% DMSO, 0.5% Tween-80
in saline, and 5,7-DHT in 45% cyclodextrin.
2.2. Western blot
Spinal cords harvested 5, 30 and 60 min after hind paw formalin
(50 ll, 2.5 %) injection were homogenized by sonication in extraction
buﬀer (50 mM Tris buﬀer), containing 0.5% Triton X-100, 150 mM
NaCl, 1 mM EDTA, Protease inhibitor cocktail (P-8340, Sigma
1:100), phosphatase inhibitor cocktail I and II (Sigma 1:100). The sam-
ples were subjected to 4–12% Bis–Tris gel electrophoresis (Invitrogen,
Carlsbad, CA) and transferred to nitrocellulose membranes (Invitro-
gen). After 1 h incubation in 5% low-fat milk the membranes were
probed with antibodies overnight at 4 C followed by HRP-conjugated
secondary antibody for 1 h at room temperature. The signal was de-
tected with chemiluminescent reagents (SuperSignal, Pierce, Rockford,
IL). The nitrocellulose membranes were then stripped with Re-blot
Western blot recycling kit (Chemicon, Temecula, CA) and incubated
with diﬀerent antibodies. Antibodies used in this study: phosphory-
lated ERK1/2 (1:1000), total ERK1/2 (1:1000) (Cell Signaling Technol-
ogy, Beverly, MA) and b-actin (1:25000) (Sigma). Intensity of
immunoreactive bands was quantiﬁed using ImageQuant software
(Molecular Dynamics, Sunnyvale, CA). ERK1/2 immuno-positive
bands were normalized relative to b-actin.
2.3. Nociceptive models
To quantify formalin induced ﬂinching, an automated sensing sys-
tem was employed [13]. Brieﬂy, a soft metal band was placed on the
hind paw of the animal being tested, and 2.5% formalin (50 ll) was
injected into the dorsal side of the banded paw. Nociceptive ﬂinching
behavior was counted for 1-min periods for 60 min.
2.4. Measurements of tissue content of 5-HT
High performance liquid chromatography (HPLC) with a ﬂuorescent
detector was employed to determine the content of 5-HT in the spinal
cord, sciatic nerve and skin of 5,7-DHT and vehicle treated rats [14].
2.5. Statistics
For measurements of protein levels by Western blotting and forma-
lin test, four to seven animals were included per group. Diﬀerences be-
tween groups were compared with one-way ANOVA and Bonferroni
post hoc test.blished by Elsevier B.V. All rights reserved.
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3.1. Injection of formalin into the paw evokes phosphorylation of
spinal ERK1/2
The formalin model is frequently used to study tissue injury
induced facilitated pain states in rodents [13]. Formalin-in-
duced hyperalgesia (i.e., phase II ﬂinches) is thought to repre-
sent spinal facilitation initiated by aﬀerent input [15]. In
agreement with the immunocytochemical studies [1,16], we
showed by Western blots that formalin paw injection produced
an increase in phosphorylation of spinal ERK1/2. Both P-
ERK1 and P-ERK2 increased profoundly in the ipsilateral
spinal cord 5 min after formalin injection with the peak eﬀects
at 30 min (four to sevenfold, P < 0.05), and returned towards
baseline levels at 60 min (Fig. 1A, B, E). There were no signif-
icant changes in P-ERK1/2 in the contralateral side (Fig. 1A,
B, E) or total protein expression of ERK1/2 at the time points
examined (Fig. 1C, D).Fig. 1. Injection of formalin to the paw activates ERK1/2 in the spinal cord. P
(Tot) ERK1 (C) and Tot-ERK2 (D) in the lumbar dorsal cord ipsilateral (ipsi
compared to naı¨ve control. The data were normalized against beta-actin (b-ac
0 min, one-way ANOVA. (E) Representative Western blots showing the
contralateral (c) spinal cords after formalin injections at the time points of 53.2. Inhibition of spinal ERK1/2 attenuates formalin induced
ﬂinching
After formalin injection, the total number of ﬂinches in the
vehicle group was 224 ± 25 in phase 1 (1–9 min), and
1360 ± 111 in phase 2 (10–60 min) (Fig. 2A). Pretreatment
with the MEK1 inhibitor PD98059 (IT, 1–30lg, 15 min prior
to formalin injection) produced a dose-dependent inhibition
of the phase 2 ﬂinching (Fig. 2A, B). The highest dose of IT
PD98059 (30 lg) reduced the second phase response in com-
parison with the vehicle group (786 ± 103 ﬂinches, P < 0.05
vs. vehicle group) without causing any sign of sedation or mo-
tor weakness.
3.3. Depletion of spinal 5-HT prevents formalin-evoked spinal
ERK1/2 phosphorylation and hyperalgesia
Two days after IT treatment with 5,7-DHT (20–60 lg), the
5-HT level in rat spinal cord was signiﬁcantly reduced, i.e.,
5-HT (nmol/mg tissue): 2.8 ± 0.5 after vehicle treatment,ercentage change of phosphorylated (P) ERK1 (A), P-ERK2 (B), Total
) or contralateral (contra) to formalin paw injection at 5, 30 and 60 min
tin) expressed in each sample. N = 4–7/group, *P < 0.05, 5 or 30 min vs.
levels of P-ERK1/2, tot ERK1/2 and b-actin in ipsilateral (ip) and
, 30 and 60 min (0 min = naı¨ve rat).
Fig. 2. Inhibition of ERK1/2 activity by blocking MEK1 activity
attenuates formalin evoked formalin induced ﬂinching. (A) Number of
ﬂinches/minute plotted versus time following injection of formalin to
the paw and IT injection of PD98059 (30 lg), or vehicle (10 ll). (B)
Histogram showing the dose–response eﬀect of IT PD98059 (1–30 lg)
on formalin test phase I and phase II ﬂinching behavior. The bars
represent the total number of ﬂinches in each phase: Phase I, 1–9 min;
Phase II, 10–60 min. The data are presented as means ± S.E.M. of 4–7
rats/group. *P < 0.05, PD98059 (30 lg) vs. vehicle, one-way ANOVA.
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tively (78–84% reduction, P < 0.05). 5,7-DHT (20 lg, IT)Fig. 3. Intrathecal pretreatment with 5,7-DHT blocks formalin-evoked phos
ERK2 (B) in the ipsilateral lumbar spinal cord 30 min after formalin paw injec
(60 lg) group. The data were normalized against beta-actin (b-actin) express
*P < 0.05, one-way ANOVA. (C) Representative Western blots showing the
after formalin injections in rats.which eﬀectively depleted the 5-HT in the spinal cord, did
not aﬀect the 5-HT content in two peripheral tissues examined,
sciatic nerve and skin (data not shown). No abnormal behav-
ior or motor functions were observed in 5,7-DHT or vehicle
treated animals. In rats pretreated with IT vehicle there was
a robust increase in spinal P-ERK1/2 observed 30 min after
injection of formalin into the paw. This elevation of spinal
P-ERK1/2 was diminished in rats treated with 5,7-DHT
(60 lg, P < 0.05, Fig. 3). In parallel with the potent inhibitory
eﬀect on activation of spinal ERK1/2, formalin-induced sec-
ond phase ﬂinching, but not ﬁrst phase, was profoundly atten-
uated in 5,7-DHT treated animals (P < 0.05, Fig. 4).
3.4. Inhibition of spinal 5-HT3 receptors attenuates formalin-
induced ERK activation and pain behavior
Intrathecal ondansetron inhibited both pain behavior and
ERK activation, in agreement with the 5,7-DHT data. Ondan-
setron, at a dose of 1–3 lg, inhibited the second phase of for-
malin (but not the ﬁrst phase) ﬂinching by 30–40% compared
to saline group (P < 0.05, Fig. 6). Expression of P-ERK1/2
was attenuated by ondansetron (1 lg), however, only inhibi-
tion of P-ERK2 reached statistical signiﬁcance (Fig. 5).4. Discussion
The present studies indicate that injury-evoked spinal P-
ERK expression is dependent on the presence of an excitatory
descending 5-HT pathway. It is known that serotonergic inner-
vation of the spinal cord is derived largely from supraspinal
sources [17]. Thus, 5,7-DHT, a neurotoxin selective for seroto-
nergic terminals [18], at IT doses that produced a 70–80%
reduction in dorsal horn 5-HT, prevented both thephorylation of spinal ERK1/2. Percentage change of P-ERK1 (A), P-
tion in the control (no formalin injection), vehicle (10 ll) and 5,7-DHT
ed in each sample and presented as means ± S.E.M. of 4–7 rats/group.
levels of P-ERK1/2, tot ERK1/2 and b-actin in ipsilateral spinal cords
Fig. 4. Depletion of spinal 5-HT prevents formalin-evoked hyperal-
gesia. (A) Flinches/minute plotted versus time after injection of
formalin in rats treated with 5,7-DHT (60 lg, IT) or vehicle (10 ll,
IT). (B) Histogram showing the dose–response eﬀect of 5,7-DHT (20–
60 lg, IT) on formalin test phase I and phase II ﬂinching behavior. The
bars represent the total number of ﬂinches in each phase. The data are
presented as means ± S.E.M. of 4–5 rats/group. *P < 0.05, 5,7-DHT
vs. vehicle, one-way ANOVA.
Fig. 5. Intrathecal injection of ondansetron reduces formalin-evoked
phosphorylation of spinal ERK1/2. Percentage change of P-ERK1 (A)
and P-ERK2 (B) in ipsilateral lumbar spinal cord 30 min after
formalin injection in the control (no formalin injection), vehicle
(saline, 10 ll) and ondansetron (ODS, 1 lg) group. The vehicle and
ondansetron were delivered IT 15 min before the formalin injection.
Reduction of formalin-evoked P-ERK1/2 by ondansetron was
observed, however, only P-ERK2 reduction reached statistical signif-
icance (*P < 0.05, one-way ANOVA, N = 4–7/group). (C) Represen-
tative Western blots showing the levels of P-ERK1/2, tot ERK1/2 and
b-actin in ipsilateral spinal cords after formalin injections in rats with
and without IT ondansetron. (D) Note: P-ERK2 showed a higher level
of phosphorylation in this experiment and in order to avoid saturation
during quantiﬁcation two diﬀerent exposure times was used for this
membrane.
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phase II ﬂinching behavior. The involvement of spinal 5-HT3
receptors is supported by the attenuation of P-ERK after IT
delivery of ondansetron, a selective 5-HT3 antagonist, at a
dose that suppressed formalin-evoked ﬂinching.
Immunocytochemical studies [1,16] have demonstrated that
shortly after peripheral formalin injection there is a marked in-
crease in the number of neurons in the dorsal horn ipsilateral
to the stimulus containing the activated (phosphorylated) form
of ERK1/2. An important issue relates to the organization of
the input that initiates phosphorylation of dorsal horn
ERK1/2. It has been shown in a variety of neuronal systems
that membrane depolarization triggered by excitatory trans-
mitters activates ERK [8]. Therefore, in the present context,
it may be argued that activation of ERK in the dorsal horn
is evoked by substance P and glutamate released from the cen-
tral terminals of primary aﬀerents. This suggestion is sup-
ported by the observations that aﬀerent-evoked activation of
spinal ERK1/2 is blocked by antagonism of neurokinin 1
(NK1) and N-methyl-D-aspartate receptors [1,16]. While it is
evident that ERK activation could be initiated by primary
aﬀerent input, spinal neuronal excitability is also regulated
by input from supraspinal sources [8]. Apart from the presence
of descending inhibitory pathways altering pain thresholds
[17,19,20], there is a growing body of data indicating the
importance of descending facilitatory pathways [6,17,21]. The
descending serotonergic system arises in the rostroventral me-
dulla, projects to the dorsal horn and exerts a potent facilita-tory eﬀect through dorsal horn 5-HT3 receptors. Thus,
formalin-induced spinal neuronal activation (assessed as cFOS
expression) and nocifensive behaviors are signiﬁcantly reduced
after either functional elimination of 5-HT3 receptors [10] or
by spinal delivery of the 5-HT3 receptor antagonists [6,7]. It
is currently thought that this facilitatory drive is initiated by
small aﬀerent input leading to activation of superﬁcial dorsal
horn NK1 receptor-bearing neurons projecting to the periaqu-
eductal grey and parabrachial area [22]. These areas connect to
spinopetal serotonergic projections via the rostral ventrome-
dial medulla [6,9] and serotonin is released in the spinal cord
Fig. 6. Blockade of spinal 5-HT3 receptors attenuates formalin-
evoked hyperalgeisa. (A) Flinches/minute plotted versus time after
injection of formalin in rats treated with IT injection of ondansetron
(ODS, 1 lg), or vehicle (saline, 10 ll). Each point represents the
number of ﬂinches per min. (B) Histogram shows inhibitory eﬀects of
IT ondasertron at doses of 1 and 3 lg on phase I and phase II ﬂinching
behavior. The bars represent the total number of ﬂinches in each
phase. The data are presented as means ± S.E.M. of 4–11 rats/group.
*P < 0.05, ODS vs. saline, one-way ANOVA.
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ent input [23]. These observations, along with our present ﬁnd-
ing that 5,7-DHT abolish formalin-induced ERK activation,
highlight the importance of descending facilitatory systems
and suggest enhancement of aﬀerent-initiated spinal ERK acti-
vation as one mechanism underlying this descending facilita-
tion.
Although there are conﬂicting reports, spinal 5-HT3 recep-
tors are considered to have predominantly excitatory functions
[6,17,24]. Immunocytochemical and in situ hybridization stud-
ies have revealed that 5-HT3 receptors are present on superﬁ-
cial dorsal horn neurons and terminals [10,25–28], a ﬁnding
consistent with the processing of nociceptive information in
the spinal cord. A proportion of the 5-HT3 receptors are lo-
cated on terminals of primary aﬀerents while others are on
dorsal horn interneurons, in particular on a subgroup of excit-
atory interneurons in lamina II that uses glutamate as neuro-
transmitter. It is known that 5-HT3 receptor channels
enhance calcium permeability and phospholipase C activity
and both events can reinforce ERK activation that is initially
triggered by neurotransmitters released from sensory aﬀerents
[1,16,17]. Our data indicate that the 5-HT3 receptors are pos-
sibly involved in descending 5-HT-mediated facilitation of
spinal ERK signaling.
In conclusion, the present ﬁndings emphasize the role of a
spino-bulbo-spinal serotonergic pathway activated by nocicep-
tive input in initiating a facilitated state of processing at the le-
vel of spinal dorsal horn. This spinopetal input acts by therelease of spinal 5-HT which works through a local 5-HT3
receptor to activate ERK-containing cell systems. These spinal
ERK systems then serve to enhance nociceptive transmission.
These studies thus show the importance of an extra-spinal link-
age in mediating aﬀerent evoked changes in local dorsal horn
excitability. It is evident that this loop pathway must now be
routinely considered in interpreting the eﬀects of aﬀerent stim-
ulation on dorsal horn function and particularly those indices
such as ERK, which mediate facilitated processing.Acknowledgements: This work was supported by NIH NS 16541. The
authors thank Alan Moore and Steve Rossi for performing 5-HT as-
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